News
RNAC
19.02
-1.30%
-0.25
Cartesian Therapeutics Price Target Announced at $42.00/Share by BTIG
Dow Jones · 1d ago
BTIG Initiates Coverage On Cartesian Therapeutics with Buy Rating, Announces Price Target of $42
Benzinga · 1d ago
Cartesian Therapeutics announces employment inducement grants
TipRanks · 3d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 3d ago
Weekly Report: what happened at RNAC last week (1209-1213)?
Weekly Report · 5d ago
Cartesian Therapeutics Files For Proposed Resale Or Other Disposition By Selling Stockholders Of Up To 6.3M Common Stock
Benzinga · 12/13 21:18
CARTESIAN THERAPEUTICS FILES FOR PROPOSED RESALE OR OTHER DISPOSITION BY SELLING STOCKHOLDERS OF UP TO 6.3 MLN COMMON STOCK - SEC FILING
Reuters · 12/13 21:14
Cartesian Therapeutics Files For Mixed Shelf Offering Of Up To $400M
Benzinga · 12/13 21:10
CARTESIAN THERAPEUTICS : SALES AGREEMENT PROSPECTUS COVERS OFFERING OF UP TO $100 MLN COMMON STOCK THAT MAY BE ISSUED FROM TIME TO TIME
Reuters · 12/13 21:08
CARTESIAN THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $400 MLN - SEC FILING
Reuters · 12/13 21:08
Insider Sale: Chief Technology Officer of $RNAC (RNAC) Sells 2,901 Shares
Barchart · 12/12 01:38
Weekly Report: what happened at RNAC last week (1202-1206)?
Weekly Report · 12/09 10:50
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Envista Holdings (NVST) and UnitedHealth (UNH)
TipRanks · 12/06 06:22
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)
TipRanks · 12/06 06:11
Promising Clinical Developments and Pivotal Trials Position Cartesian Therapeutics for Long-term Success
TipRanks · 12/06 05:57
Cartesian Therapeutics Price Target Raised to $45.00/Share From $41.00 by HC Wainwright & Co.
Dow Jones · 12/04 11:51
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Raises Price Target to $45
Benzinga · 12/04 11:41
Cartesian Therapeutics Announces Phase 3 AURORA Trial for Descartes-08 in Myasthenia Gravis Set to Begin in 1H2025
Barchart · 12/03 15:12
Cartesian Therapeutics Reports Promising Phase 2b Trial Results
TipRanks · 12/03 11:33
Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia
TipRanks · 12/03 11:10
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.